Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2204]

FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumour expression ≥1%)

FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumour expression ≥1%)

FDA approves ripretinib for advanced gastrointestinal stromal tumour

FDA approves ripretinib for advanced gastrointestinal stromal tumour

FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer

FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer

FDA grants accelerated approval to pomalidomide for Kaposi sarcoma

FDA grants accelerated approval to pomalidomide for Kaposi sarcoma

Treatment guidance for lung cancer patients during the COVID-19 pandemic

Treatment guidance for lung cancer patients during the COVID-19 pandemic

ASCO 2020: Video conference intervention significantly reduces anxiety and distress among remote caregivers of people with cancer

ASCO 2020: Video conference intervention significantly reduces anxiety and distress among remote caregivers of...

FDA approves selpercatinib for lung and thyroid cancers with RET gene mutations or fusions

FDA approves selpercatinib for lung and thyroid cancers with RET gene mutations or fusions

FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer

FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer

Approval of targeted therapies first line for prostate cancer ‘will ease Covid-19 pressures’

Approval of targeted therapies first line for prostate cancer ‘will ease Covid-19 pressures’

High cost of cancer drugs not always justified

High cost of cancer drugs not always justified

More from ecancer